US biotechnology startup Conception has announced that it has generated early-stage human egg cells, known as primary oocytes, from stem cells created from blood samples. The company said the cells remain immature and cannot currently be used for fertilization or pregnancy. The company reported that the achievement involved converting blood cells into induced pluripotent stem …
Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide and continues to be a major healthcare concern in 2026. According to leading cancer research organizations, prostate cancer accounts for a significant percentage of new cancer diagnoses each year, highlighting the ongoing need for more accurate, less invasive diagnostic tools. Recent advancements …
Next-Generation Flexible Robots Are Transforming Minimally Invasive Gastrointestinal Procedures The field of robotic-assisted surgery continues to evolve rapidly in 2026, with flexible robotic endoscopy emerging as one of the most promising innovations in minimally invasive healthcare. Originally pioneered through the MASTER (Master and Slave Transluminal Endoscopic Robot) platform developed by researchers at Nanyang Technological University …
The Coalition for Epidemic Preparedness Innovations has committed more than US$60 million to Moderna and other vaccine groups to speed the development of investigational vaccines against Bundibugyo ebolavirus, as health authorities respond to an outbreak affecting the Democratic Republic of the Congo and Uganda. The largest part of the package is up to US$50 million …
Goldman Sachs Boosts S&P 500 Target to 8,000 on Robust Earnings Outlook, Signaling Tailwinds for MedTech M&A and Innovation Funding Key Takeaways: Goldman Sachs raised its 2026 year-end S&P 500 target from 7,600 to 8,000, implying ~6.4% upside from the recent close of 7,519.12. The firm hiked 2026 S&P 500 EPS forecasts to $340 (24% …
Pfizer Inc. continues to strengthen its position in the global vaccines sector through targeted development programs and updates to existing offerings. As a major player in this field, the company focuses on respiratory diseases, bacterial infections, and emerging threats, aligning with broader industry trends of innovation in mRNA platforms and combination vaccines. In 2025, Pfizer …
Evonik Industries AG is expanding its capabilities in lipid nanoparticle (LNP) development and manufacturing as demand for RNA therapeutics, mRNA vaccines, and nucleic acid drug delivery continues to increase globally. The company has announced multiple investments, technology partnerships, and manufacturing expansions aimed at supporting pharmaceutical and biotechnology companies developing advanced therapies. According to the company, …